Phase 2 Hearing Loss Trial, Recruiting (NCT06591793)

Phase 2 Hearing Loss Trial, Recruiting NCT06591793 Sponsor: AAVantgarde Bio Srl Condition: Hearing Loss

Printed from Voxsanity (voxsanity.com.au) — NCT06591793 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hearing Loss

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with Usher Syndrome Type 1B through genetic testing, specifically caused by a change (mutation) in a gene called MYO7A
You are willing and able to follow all the requirements of the study, as explained in the consent process

Who may not be able to join:

You are unwilling or unable to meet the requirements of the study
You have taken part in another clinical trial using an investigational (experimental) product within the last 6 months
You have previously taken part in a gene therapy trial of any kind
You have any health condition that would make a specific type of eye surgery (called subretinal surgery) unsafe or not possible for you (confirm with trial site)
You have other significant eye conditions or other serious health conditions that could interfere with the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +448000465680

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06591793

Sponsor: AAVantgarde Bio Srl

Phase: Phase 2

Status: Recruiting

Condition: Hearing Loss

Trial contact: +448000465680

More information: https://clinicaltrials.gov/study/NCT06591793

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with Usher Syndrome Type 1B through genetic testing, specifically caused by a change (mutation) in a gene called MYO7A
You are willing and able to follow all the requirements of the study, as explained in the consent process

Who may not be able to join:

You are unwilling or unable to meet the requirements of the study
You have taken part in another clinical trial using an investigational (experimental) product within the last 6 months
You have previously taken part in a gene therapy trial of any kind
You have any health condition that would make a specific type of eye surgery (called subretinal surgery) unsafe or not possible for you (confirm with trial site)
You have other significant eye conditions or other serious health conditions that could interfere with the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

AAVantgarde Bio Srl

Registry

ClinicalTrials.gov

Start date

2 July 2024

Est. completion

1 July 2025

Where this trial is recruiting

🇮🇹 Italy 🇬🇧 United Kingdom

Primary endpoints

To measure the number and severity of treatment related adverse events following treatment with AAVB-081

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov